Basic Facts about Biosimilars

Publisher： Karger

E-ISSN： 1423-0143|30|5|267-272

ISSN： 1420-4096

Source： Kidney and Blood Pressure Research, Vol.30, Iss.5, 2007-07, pp. : 267-272

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Manufacturing of Biopharmaceuticals and Implications for Biosimilars

By  

Kidney and Blood Pressure Research, Vol. 30, Iss. 1, 2007-08 ,pp. : 6-8

Karger

Access to resources Recommend Favorite

Biosimilars in Clinical Practice

By  

Kidney and Blood Pressure Research, Vol. 30, Iss. 1, 2007-08 ,pp. : 18-22

Karger

Access to resources Recommend Favorite

EMEA Guidelines on Biosimilars and Their Clinical Implications

By  

Kidney and Blood Pressure Research, Vol. 30, Iss. 1, 2007-08 ,pp. : 13-17

Karger

Access to resources Recommend Favorite

Biosimilars and Renal Health Care in the Countries of Central and Eastern Europe

By  

Kidney and Blood Pressure Research, Vol. 30, Iss. 1, 2007-08 ,pp. : 2-5

Karger

Access to resources Recommend Favorite

History of Erythropoiesis-Stimulating Agents, the Development of Biosimilars, and the Future of Anemia Treatment in Nephrology

By  

American Journal of Nephrology, Vol. 45, Iss. 3, 2017-02 ,pp. : 235-247

Karger

Access to resources Recommend Favorite